Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company headquartered in Burlingame, Washington, continues to make strides in the biotechnology sector with its innovative approach to cancer treatment. The company, which specializes in developing novel and first-in-class agents targeting the immune system, aims to revolutionize cancer therapy by leveraging the body’s natural defense mechanisms.
As of April 1, 2026, Corvus Pharmaceuticals is listed on the Nasdaq stock exchange, where its shares closed at $14.69. The company’s market capitalization stands at approximately $1.23 billion. Despite its promising developments in the field of oncology, the company’s price-to-earnings ratio is currently at -27.42, reflecting the challenges often faced by clinical-stage biopharmaceutical companies in achieving profitability.
Corvus Pharmaceuticals’ journey began with its Initial Public Offering (IPO) on March 23, 2016. Since then, the company has focused on advancing its pipeline of immune-targeting therapies. These therapies are designed to enhance the immune system’s ability to combat cancer, offering a potential paradigm shift in treatment methodologies.
Throughout its history, Corvus Pharmaceuticals has experienced significant fluctuations in its stock price. The 52-week high was recorded at $26.95 on January 22, 2026, while the 52-week low was $2.54 on April 8, 2025. These variations highlight the volatile nature of the biotechnology sector, particularly for companies in the clinical development phase.
Corvus Pharmaceuticals operates primarily within the United States, where it continues to pursue its mission of transforming cancer treatment through cutting-edge research and development. The company’s focus on immune system modulation positions it at the forefront of biotechnological innovation, with the potential to significantly impact patient outcomes in oncology.
As Corvus Pharmaceuticals progresses through its clinical trials and continues to refine its therapeutic agents, the biotechnology community and investors alike will be closely monitoring its developments. The company’s commitment to pioneering new treatments underscores its role as a key player in the ongoing battle against cancer.
